Skip to main content
. 2022 Apr 20;28(15):3356–3366. doi: 10.1158/1078-0432.CCR-21-2834

Figure 2.

Figure 2. Standard-of-care first-line platinum-based chemotherapy increases T-cell responses to viral antigens following chemotherapy. A, IFNγ ELISpot responses to influenza (FluA) and CEF peptide pools over the course of chemotherapy in patient 6 (CA125 complete responder). OKT CD3 (anti-CD3ε antibody) served as a positive control. B and C, IFNγ ELISpot responses to FluA and CEF peptide pools over the course of chemotherapy in CA125 complete responders (Pts. 1, 2, 4, and 6; B) and CA125 incomplete responders (Pts. 7, 8, and 10; C). Spot-forming cell (SFC) per 106 PBMCs were background (OVA)-subtracted with n = 3 biologically independent samples. All data points represent mean ± standard error of the mean (s.e.m.). A repeated-measures regression model was used for generating P values; *, P ≤ 0.05.

Standard-of-care first-line platinum-based chemotherapy increases T-cell responses to viral antigens following chemotherapy. A, IFNγ ELISpot responses to influenza (FluA) and CEF peptide pools over the course of chemotherapy in patient 6 (CA125 complete responder). OKT CD3 (anti-CD3ε antibody) served as a positive control. B and C, IFNγ ELISpot responses to FluA and CEF peptide pools over the course of chemotherapy in CA125 complete responders (Pts. 1, 2, 4, and 6; B) and CA125 incomplete responders (Pts. 7, 8, and 10; C). Spot-forming cell (SFC) per 106 PBMCs were background (OVA)-subtracted with n = 3 biologically independent samples. All data points represent mean ± standard error of the mean (s.e.m.). A repeated-measures regression model was used for generating P values; *, P ≤ 0.05.